Core Insights - The article highlights the transformation of China's pharmaceutical industry from a "big pharmaceutical country" to a "strong pharmaceutical country," emphasizing the importance of high-quality development and innovation in the sector [2][3] Group 1: Event Overview - The "High-Quality Development Research Tour of Domestic Medicines" was successfully held in Jinan, Shandong, from June 4 to June 6, 2025, organized by the China Pharmaceutical News Information Association and Beijing Daily Client [1] - The event involved over 20 major media outlets, focusing on the research and innovation platform, quality management system, and intelligent production base of Qilu Pharmaceutical [1] Group 2: Qilu Pharmaceutical's Achievements - Qilu Pharmaceutical has won 7 National Science and Technology Progress Awards and has 208 products listed in the National Medical Insurance Directory as of June 2025 [2] - The company has achieved leadership in the industry in terms of consistency evaluation, first-time evaluations, and national procurement bidding [2] - Qilu's R&D investment has increased from 5%-8% of sales revenue to 10%-12%, with an expected cumulative investment exceeding 20 billion yuan during the 14th Five-Year Plan period [3] Group 3: International Expansion - Qilu Pharmaceutical is the only domestic company exporting formulations to major regulatory markets including Europe, the US, Japan, Australia, and Canada, with 38 products holding the top market share in their respective regions [4] - The company's export revenue reached 1.02 billion USD in 2024 [4] Group 4: Technological Innovations - Qilu has developed groundbreaking technologies such as dual-function combination antibody preparation technology and large-scale cell culture technology, establishing an internationally leading MabPair combination antibody technology platform [6] - The company has implemented fully automated production lines, ensuring quality consistency and traceability throughout the production process [5] Group 5: Industry Dialogue - A seminar titled "Quality Leads, Good Medicines Accessible" was held during the research tour, where experts discussed the need for improved public perception of domestic medicines and the importance of collaborative efforts among media, academia, and regulatory bodies [6] - Qilu has 15 products among those selected in national procurement that rank highly in the US market [6] Group 6: Future Directions - The "High-Quality Development Research Tour of Domestic Medicines" will continue to focus on the pharmaceutical industry, expanding research to more domestic pharmaceutical companies across the country [7]

Core Viewpoint - The stock price of Bohan Biotech (06955) has declined over 30% since reaching a peak of 19.90 HKD on August 8, 2023, and is now facing pressure to maintain its status in the Hong Kong Stock Connect due to a decrease in average market capitalization [1][2] Group 1: Stock Performance - Bohan Biotech's average market capitalization has fallen to 6.651 billion HKD, approaching the Hong Kong Stock Connect exit threshold of 5.745 billion HKD [1] - The stock has been in a downward trend characterized by "price drop and volume shrinkage" since August, with significant trading volume declines observed [2][3] - On October 14, the stock price reached a low of 11.22 HKD, but there are signs of stabilization in the following trading days [1][5] Group 2: Market Dynamics - The company has faced challenges due to the introduction of centralized procurement for biosimilars, which could impact its valuation and market position [1][6] - Bohan Biotech's strategy of developing biosimilars has been crucial for its commercial success, but the centralized procurement poses a risk to its business model [6][7] - The centralized procurement initiated on August 1, 2023, includes several key monoclonal antibodies, directly affecting Bohan Biotech's products [7][8] Group 3: Competitive Landscape - Bohan Biotech's core product, Bevacizumab (博优诺®), faces intense competition with 11 approved biosimilars in the market, leading to price pressures [8][9] - The company has partnered with AstraZeneca for the exclusive promotion of Bevacizumab, but its market share remains low compared to competitors [8] - The pricing strategy post-procurement will be critical, as Bohan Biotech's pricing is competitive but may still struggle against established players [9]